U.S. Doesn't Know Beans About Genes

WASHINGTON—Two recent public opinion surveys indicate that a substantial majority of adult Americans do not know what genetic engineering is and are ignorant of the ethical and scientific issues surrounding it. Nearly two in five people (39 percent) had not heard of genetic engineering, according to a survey conducted last spring for Novo Laboratories, a pharmaceutical company. The poll also found that nearly two-thirds of the remaining group—representing a total of 80 percent o

Written byTed Agres
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WASHINGTON—Two recent public opinion surveys indicate that a substantial majority of adult Americans do not know what genetic engineering is and are ignorant of the ethical and scientific issues surrounding it.

Nearly two in five people (39 percent) had not heard of genetic engineering, according to a survey conducted last spring for Novo Laboratories, a pharmaceutical company. The poll also found that nearly two-thirds of the remaining group—representing a total of 80 percent of the overall sample—felt insufficiently informed to comment on regulatory issues. A survey done last fall for the congressional Office of Technology Assessment (see THE SCIENTIST, June 29, p.4) found that more than 63 percent of those polled said they knew little or nothing about the field.

Plunging ahead in the face of such ignorance, the examiners found a broad base of support for genetic engineering research and application, with large percentages believing that benefits will accrue ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies